Dr. Hyo (Heather) Han, Research Director and medical oncologist in Moffitt's Breast Cancer Oncology Department, presented the results of the BROCADE3 study at ASCO 2020. BROCADE3, a phase III study, investigates the use of Veliparib monotherapy (a PARP inhibitor) following combination therapy with Veliparib+ carboplatin/paclitaxel in patients with germline BRCA-associated advanced breast cancer.
The study included 590 randomized patients who received either Veliparib monotherapy or a placebo in a 2:1 ratio to determine the safety and efficacy of Veliparib monotherapy following Veliparib combined with chemotherapy. The analysis suggests that the overall progression free survival benefit comes from Veliparib monotherapy with a combination of carboplatin/paclitaxel and from continued Veliparib treatment after discontinuing chemotherapy prior to disease progression. Therefore, Veliparib may be a suitable treatment following the use of combination chemotherapy for a limited duration.
To learn more about breast cancer clinical trials or to refer a patient, complete our online form or contact a physician liaison for assistance or support. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.